Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
S. Cyrus Khojasteh, Namandjé N. Bumpus, James P. Driscoll, Grover P. Miller, Kaushik Mitra, Ivonne M. C. M. Rietjens & Donglu Zhang. (2019) Biotransformation and bioactivation reactions – 2018 literature highlights. Drug Metabolism Reviews 51:2, pages 121-161.
Read now
Read now
Isabella Esposito, Sebastián Marciano & Julieta Trinks. (2018) Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C. Expert Opinion on Drug Metabolism & Toxicology 14:6, pages 649-657.
Read now
Read now
Articles from other publishers (10)
Sayaka Deguchi, Tomohiro Shintani, Kazuo Harada, Toru Okamoto, Akinori Takemura, Kazumasa Hirata, Kousei Ito, Kazuo Takayama & Hiroyuki Mizuguchi. (2021) In Vitro Model for a Drug Assessment of Cytochrome P450 Family 3 Subfamily A Member 4 Substrates Using Human Induced Pluripotent Stem Cells and Genome Editing Technology. Hepatology Communications 5:8, pages 1385-1399.
Crossref
Crossref
W.M.A. Niessen. (2020) Tandem mass spectrometry of small-molecule antiviral drugs: 2. hepatitis-related antivirals. International Journal of Mass Spectrometry 455, pages 116371.
Crossref
Crossref
Jun Matsumoto, Su Nwe San, Masachika Fujiyoshi, Ayano Kawauchi, Natsumi Chiba, Ran Tagai, Ryoko Sanbe, Shiho Yanaka, Hiroaki Sakaue, Yoshinori Kato, Hiroyoshi Nakamura, Harumi Yamada & Noritaka Ariyoshi. (2019) Effect of CYP3A5*3 genetic variant on the metabolism of direct-acting antivirals in vitro: a different effect on asunaprevir versus daclatasvir and beclabuvir. Journal of Human Genetics 65:2, pages 143-153.
Crossref
Crossref
Mayu Osawa, Takayo Ueno, Tomomi Shiozaki, Hiroki Ishikawa, Hanbin Li & Tushar Garimella. (2019) Population Pharmacokinetic Analysis of Daclatasvir, Asunaprevir, and Beclabuvir Combination in HCV-Infected Subjects. Clinical Pharmacology in Drug Development 8:6, pages 802-817.
Crossref
Crossref
Nicholas A. Meanwell, Ramkumar Rajamani, Paul M. Scola & Li-Qiang Sun. 2019. HCV: The Journey from Discovery to a Cure. HCV: The Journey from Discovery to a Cure
317
354
.
Mayu Osawa, Takayo Ueno, Hiroki Ishikawa, Yasuhiko Imai & Tushar Garimella. (2018) Population Pharmacokinetic Analysis for Daclatasvir and Asunaprevir in Japanese Subjects With Chronic Hepatitis C Virus Infection. The Journal of Clinical Pharmacology 58:11, pages 1468-1478.
Crossref
Crossref
Li Zhu, Hanbin Li, Phyllis Chan, Timothy Eley, Yash Gandhi, Marc Bifano, Mayu Osawa, Takayo Ueno, Eric Hughes, Malaz AbuTarif, Richard Bertz & Tushar Garimella. (2018) Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection. Infectious Diseases and Therapy 7:2, pages 261-275.
Crossref
Crossref
Chungang Gu, Markus Artelsmair, Charles S. Elmore, Richard J. Lewis, Patty Davis, James E. Hall, Bruce T. Dembofsky, Greg Christoph, Mark A. Smith, Marc Chapdelaine & Maria Sunzel. (2018)
Late-occurring and Long-circulating Metabolites of GABA
A
α
2,3
Receptor Modulator AZD7325 Involving Metabolic Cyclization and Aromatization: Relevance to MIST Analysis and Application for Patient Compliance
. Drug Metabolism and Disposition 46:3, pages 303-315.
Crossref
Crossref
Timothy Eley, Tushar Garimella, Wenying Li & Richard J. Bertz. (2017) Asunaprevir: An HCV Protease Inhibitor With Preferential Liver Distribution. Clinical Pharmacology in Drug Development 6:2, pages 195-200.
Crossref
Crossref
Y. Cheng, L. Ma, S.-Y. Chang, W. G. Humphreys & W. Li. (2016) Application of Static Models to Predict Midazolam Clinical Interactions in the Presence of Single or Multiple Hepatitis C Virus Drugs. Drug Metabolism and Disposition 44:8, pages 1372-1380.
Crossref
Crossref